Features and properties of ibalizumab

Alternative names	Trogarzo™, ibalizumab-uiyk, TMB-355, TNX-355, TMB-355, Hu5A8, monoclonal antibody 5A8
Class	CD4-directed post-attachment HIV-1 inhibitor, Antiretrovirals, Humanized monoclonal antibodies
Mechanism of Action	Binds to domain 2 of the CD4 receptor
Route of Administration	Intravenous
Pharmacodynamics	Blocks HIV-1 infection in CD4 T-cells
Pharmacokinetics	Cmax 402 µg/ml, AUCall 3604 µg · day/ml, t½ 3.3 days, volume of distribution 44 ml/kg, steady state clearance 5.7 ml/day/kg
Adverse events
Most frequent	Diarrhoea, dizziness, nausea, rash
ATC codes
WHO ATC code	J05A-X (Other antivirals)
EphMRA ATC code	J5C4 (HIV antivirals, entry inhibitors)
Chemical name	Immunoglobulin G4, anti-(human CD4 (antigen)) (human-mouse monoclonal 5A8 γ4-chain), disulphide with human-mouse monoclonal 5A8 κ-chain, dimer